Oral Semaglutide a ‘PIONEER’ in the Treatment of Type 2 Diabetes

The PIONEER 1 clinical trial was focused on the new oral GLP-1 receptor agonist semaglutide. In the PIONEER 1 trial, oral semaglutide was given to patients with a relatively short history of type 2 diabetes who had been treated with diet and exercise. https://www.medscape.com/viewarticle/903356